| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Alkermes plc. | Director | Ordinary Shares | 20.8K | $631K | $30.38 | May 31, 2025 | By the Snyderman Trust |
| Alkermes plc. | Director | Non Qualified Stock Option (Right to Buy) | 17.5K | $537K | $30.72 | May 31, 2024 | Direct |
| Alkermes plc. | Director | Ordinary Shares | 10.7K | $328K | $30.61 | May 31, 2025 | Direct |
| Future Health ESG Corp. | Director | Common stock, par value $0.0001 per share | 11.3K | $134K | $11.91 | Oct 24, 2021 | Indirect |
| Future Health ESG Corp. | Director | Common stock, par value $0.0001 per share | 11.3K | $134K | $11.91 | Oct 24, 2021 | Direct |
| Axonics, Inc. | Director | Common Stock | 0 | $0 | $71.00 | Nov 15, 2024 | Direct |
| Axonics, Inc. | Director | Stock Option (Right to Buy) | 0 | $0 | $49.96 | Nov 15, 2024 | Direct |
| Lyra Therapeutics, Inc. | Director | Restricted Stock Units | 32K | May 14, 2025 | Direct | ||
| Lyra Therapeutics, Inc. | Director | Stock Option | 30K | Jun 13, 2024 | Direct | ||
| Future Health ESG Corp. | Director | Warrant | 27.4K | Sep 14, 2021 | Indirect | ||
| Alkermes plc. | Director | Non Qualified Stock Option (Right to Buy) | 13.5K | May 21, 2025 | Direct | ||
| Alkermes plc. | Director | Restricted Stock Unit Award | 0 | May 31, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ALKS | Alkermes plc. | May 31, 2025 | 3 | -$58.9K | 4 | Jun 2, 2025 | Director |
| ALKS | Alkermes plc. | May 21, 2025 | 2 | $0 | 4 | May 23, 2025 | Director |
| LYRA | Lyra Therapeutics, Inc. | May 14, 2025 | 1 | $0 | 4 | May 16, 2025 | Director |
| AXNX | Axonics, Inc. | Nov 15, 2024 | 3 | -$1.71M | 4 | Nov 15, 2024 | Director |
| AXNX | Axonics, Inc. | Nov 7, 2024 | 1 | $0 | 4 | Nov 12, 2024 | Director |
| ALKS | Alkermes plc. | Jun 29, 2024 | 3 | -$35.3K | 4 | Jul 1, 2024 | Director |
| LYRA | Lyra Therapeutics, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
| ALKS | Alkermes plc. | May 31, 2024 | 13 | $115K | 4 | Jun 4, 2024 | Director |
| ALKS | Alkermes plc. | Jul 7, 2023 | 3 | -$42.7K | 4 | Jul 10, 2023 | Director |
| LYRA | Lyra Therapeutics, Inc. | Jun 30, 2023 | 1 | $0 | 4 | Jul 5, 2023 | Director |
| ALKS | Alkermes plc. | Jun 29, 2023 | 2 | $0 | 4 | Jun 30, 2023 | Director |
| AXNX | Axonics, Inc. | Jun 26, 2023 | 1 | $0 | 4 | Jun 28, 2023 | Director |
| AXNX | Axonics, Inc. | Aug 18, 2022 | 1 | $0 | 4 | Aug 22, 2022 | Director |
| ALKS | Alkermes plc. | Jul 7, 2022 | 2 | $0 | 4 | Jul 8, 2022 | Director |
| LYRA | Lyra Therapeutics, Inc. | Jun 16, 2022 | 1 | $0 | 4 | Jun 21, 2022 | Director |
| ALKS | Alkermes plc. | Jun 14, 2022 | 3 | -$18.9K | 4 | Jun 16, 2022 | Director |
| ALKS | Alkermes plc. | Mar 4, 2022 | 1 | $10K | 4 | Mar 8, 2022 | Director |
| ALKS | Alkermes plc. | Dec 2, 2021 | 3 | -$29.6K | 4 | Dec 3, 2021 | Director |
| FHLT | Future Health ESG Corp. | Oct 24, 2021 | 2 | $0 | 4 | Oct 26, 2021 | Director |
| AXNX | Axonics, Inc. | Oct 22, 2021 | 1 | $0 | 4 | Nov 2, 2021 | Director |
| FHLT | Future Health ESG Corp. | Sep 14, 2021 | 1 | $27.4K | 4 | Sep 16, 2021 | Director |
| FHLT | Future Health ESG Corp. | Sep 9, 2021 | 0 | $0 | 3 | Sep 9, 2021 | Director |
| ALKS | Alkermes plc. | Jun 14, 2021 | 2 | $0 | 4 | Jun 16, 2021 | Director |
| LYRA | Lyra Therapeutics, Inc. | May 26, 2021 | 1 | $0 | 4 | May 28, 2021 | Director |
| ALKS | Alkermes plc. | May 20, 2021 | 3 | -$30.8K | 4 | May 21, 2021 | Director |